Comments

Catalyst Pharmaceuticals

CPRXNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$18.00
0.442.51%
Last update: 9:04 AM
15 minutes delayed
Q2 2024 Earnings in 14 days from now on Wed Aug 7th, after the market close
Catalyst Pharmaceuticals (CPRX) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$34.00
Lowest Price Target1
$15.50
Consensus Price Target1
$24.81

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock, Analyst Ratings, Price Targets, Forecasts

Catalyst Pharmaceuticals Inc has a consensus price target of $24.81 based on the ratings of 8 analysts. The high is $34 issued by Cantor Fitzgerald on March 22, 2024. The low is $15.5 issued by Roth Capital on August 24, 2022. The 3 most-recent analyst ratings were released by Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co. on June 6, 2024, June 3, 2024, and May 10, 2024, respectively. With an average price target of $27 between Oppenheimer, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 50.00% upside for Catalyst Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
4
Mar
0
0
0
0
May
1
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Oppenheimer
HC Wainwright & Co.
Cantor Fitzgerald
Citigroup
B of A Securities

1calculated from analyst ratings

Analyst Ratings for Catalyst Pharmaceuticals

Buy NowGet Alert
06/06/2024Buy Now61.11%Oppenheimer
Leland Gershell
$29 → $29ReiteratesOutperform → OutperformGet Alert
06/03/2024Buy Now44.44%HC Wainwright & Co.
Andrew Fein
$26 → $26ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now44.44%HC Wainwright & Co.
Andrew Fein
$24 → $26MaintainsBuyGet Alert
03/27/2024Buy Now61.11%Oppenheimer
Leland Gershell
$29 → $29ReiteratesOutperform → OutperformGet Alert
03/22/2024Buy Now88.89%Cantor Fitzgerald
Charles Duncan
 → $34ReiteratesOverweight → OverweightGet Alert
03/14/2024Buy Now88.89%Cantor Fitzgerald
Charles Duncan
 → $34ReiteratesOverweight → OverweightGet Alert
03/14/2024Buy Now50%Citigroup
Samantha Semenkow
 → $27Initiates → BuyGet Alert
03/07/2024Buy Now27.78%B of A Securities
Jason Gerberry
 → $23Initiates → BuyGet Alert
03/01/2024Buy Now88.89%Cantor Fitzgerald
Charles Duncan
$27 → $34MaintainsOverweightGet Alert
03/01/2024Buy Now33.33%HC Wainwright & Co.
Andrew Fein
 → $24ReiteratesBuy → BuyGet Alert
12/21/2023Buy Now66.67%Oppenheimer
Leland Gershell
 → $30Initiates → OutperformGet Alert
08/22/2023Buy Now50%Cantor Fitzgerald
Charles Duncan
 → $27ReiteratesOverweight → OverweightGet Alert
08/11/2023Buy Now50%Cantor Fitzgerald
Charles Duncan
$25 → $27MaintainsOverweightGet Alert
08/11/2023Buy Now33.33%HC Wainwright & Co.
Andrew Fein
 → $24ReiteratesBuy → BuyGet Alert
07/21/2023Buy Now33.33%HC Wainwright & Co.
Andrew Fein
 → $24ReiteratesBuy → BuyGet Alert
06/21/2023Buy Now33.33%Truist Securities
Joon Lee
$22 → $24MaintainsBuyGet Alert
06/21/2023Buy Now38.89%Cantor Fitzgerald
Charles Duncan
 → $25ReiteratesOverweight → OverweightGet Alert
06/20/2023Buy Now33.33%Truist Securities
Joon Lee
$22 → $24MaintainsBuyGet Alert
05/12/2023Buy Now33.33%HC Wainwright & Co.
Andrew Fein
 → $24ReiteratesBuy → BuyGet Alert
03/20/2023Buy Now33.33%HC Wainwright & Co.
Andrew Fein
 → $24Reiterates → BuyGet Alert
01/19/2023Buy Now22.22%Truist Securities
Joon Lee
$18 → $22MaintainsBuyGet Alert
12/21/2022Buy Now—Truist Securities
Joon Lee
$17 → $18MaintainsBuyGet Alert
12/21/2022Buy Now33.33%HC Wainwright & Co.
Andrew Fein
$18 → $24MaintainsBuyGet Alert
12/20/2022Buy Now11.11%Piper Sandler
Joseph Catanzaro
$18 → $20MaintainsOverweightGet Alert
08/24/2022Buy Now-13.89%Roth Capital
Scott Henry
$10 → $15.5DowngradeBuy → NeutralGet Alert
08/11/2022Buy Now-5.56%Truist Securities
Joon Lee
$12 → $17MaintainsBuyGet Alert
08/11/2022Buy Now—HC Wainwright & Co.
Andrew Fein
$12 → $18MaintainsBuyGet Alert
02/08/2022Buy Now-33.33%HC Wainwright & Co.
Andrew Fein
$9 → $12MaintainsBuyGet Alert

FAQ

Q

What is the target price for Catalyst Pharmaceuticals (CPRX) stock?

A

The latest price target for Catalyst Pharmaceuticals (NASDAQ:CPRX) was reported by Oppenheimer on June 6, 2024. The analyst firm set a price target for $29.00 expecting CPRX to rise to within 12 months (a possible 61.11% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Catalyst Pharmaceuticals (CPRX)?

A

The latest analyst rating for Catalyst Pharmaceuticals (NASDAQ:CPRX) was provided by Oppenheimer, and Catalyst Pharmaceuticals reiterated their outperform rating.

Q

When was the last upgrade for Catalyst Pharmaceuticals (CPRX)?

A

There is no last upgrade for Catalyst Pharmaceuticals

Q

When was the last downgrade for Catalyst Pharmaceuticals (CPRX)?

A

The last downgrade for Catalyst Pharmaceuticals Inc happened on August 24, 2022 when Roth Capital changed their price target from $10 to $15.5 for Catalyst Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Catalyst Pharmaceuticals (CPRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Catalyst Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Catalyst Pharmaceuticals was filed on June 6, 2024 so you should expect the next rating to be made available sometime around June 6, 2025.

Q

Is the Analyst Rating Catalyst Pharmaceuticals (CPRX) correct?

A

While ratings are subjective and will change, the latest Catalyst Pharmaceuticals (CPRX) rating was a reiterated with a price target of $29.00 to $29.00. The current price Catalyst Pharmaceuticals (CPRX) is trading at is $18.00, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch